高级检索
当前位置: 首页 > 详情页

Nucleic acid-sensing-related gene signature in predicting prognosis and treatment efficiency of small cell lung cancer patients

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Guangxi Med Univ, Affiliated Canc Hosp, Dept Hepatobiliary Surg, Nanning, Peoples R China [2]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Acad Med Sci, Dept Oncol, Chengdu, Peoples R China [3]Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Sichuan Prov Peoples Hosp, Canc Inst, Chengdu, Peoples R China [4]YuceBio Technol Co Ltd, Shenzhen Engn Ctr Translat Med Precis Canc Immunod, Shenzhen, Peoples R China
出处:
ISSN:

关键词: small cell lung cancer nucleic acid sensing-related genes prognostic signature tumor microenvironment multiplex immunohistochemistry

摘要:
Introduction Nucleic acid-sensing (NAS) pathways could induce innate and adaptive immune responses. However, rare evidence exhibited how the core genes of the NAS pathways affected the immune response and prognosis of small cell lung cancer (SCLC) patients.Methods We conducted a comprehensive bioinformatic analysis based on the RNA profiles of 114 SCLC patients, including 79 from cBioPortal, 21 from GSE30219, and 14 from our sequencing data. The multiplex immunohistochemistry (mIHC) was used to characterize the role of NAS related genes in the tumor microenvironment (TME) of SCLC.Results A prognostic model (7NAS risk model) was constructed based on 7 NAS-related genes which was demonstrated as an independent prognostic index. The low-risk group was identified to have a better prognosis and an immune-activated microenvironment in both the public datasets and our dataset. Intriguingly, mIHC data showed that CD45+ immune cells, CD8+ T lymphocytes, and CD68+ macrophages were prevalently enriched in low-risk SCLC patients and positively correlated with IRF1 expression. Additionally, Patients in the low-risk group might have superior responses to chemotherapy and immunotherapy.Conclusion Conclusively, this study created a new risk model based on genes associated with NAS pathways which could predict the prognosis and response of treatment in patients with SCLC.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2023]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Guangxi Med Univ, Affiliated Canc Hosp, Dept Hepatobiliary Surg, Nanning, Peoples R China [2]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Acad Med Sci, Dept Oncol, Chengdu, Peoples R China [3]Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Sichuan Prov Peoples Hosp, Canc Inst, Chengdu, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [2]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Acad Med Sci, Dept Oncol, Chengdu, Peoples R China [3]Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Sichuan Prov Peoples Hosp, Canc Inst, Chengdu, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号